Show simple item record

dc.contributor.authorHermann, Dirk M
dc.contributor.authorPopa-Wagner, Aurel
dc.contributor.authorKleinschnitz, Christoph
dc.contributor.authorDoeppner, Thorsten R
dc.date.accessioned2019-09-03T00:12:30Z
dc.date.available2019-09-03T00:12:30Z
dc.date.issued2019
dc.identifier.issn1746-0441en_US
dc.identifier.doi10.1080/17460441.2019.1573984en_US
dc.identifier.urihttp://hdl.handle.net/10072/386878
dc.description.abstractIntroduction: Representing the leading cause of long-term disability, ischemic stroke urgently needs further research and drug development. This review summarizes current animal models of ischemic stroke that can be used for drug discovery. Areas covered: Several reproducible models of permanent and transient focal cerebral ischemia have been established in a variety of animal species including rats and mice, in which a brain-supplying artery, often the middle cerebral artery, is occluded by mechanical devices including sutures, clips and hooks, pharmacological agents or delivery of blot clots. The authors review existing literature about these models, outlining their utility for evaluating acute and post-acute stroke treatments. Since stroke is an age-related disease that strongly affects humans with vascular risk factors and co-morbidities, the authors give focus to strategies replicating risk factors in ischemic stroke models. Furthermore, the authors present models of spontaneous stroke. Expert opinion: It is important that animal models mimic clinical conditions in a reliable and clinically relevant way, so here, they should replicate the pathophysiology of human stroke, stroke-associated risk factors and doses, times and modes of drug treatment. We propose that risk factor models should more widely be used in early drug discovery, if possible already during the identification of treatment targets.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherTaylor & Francisen_US
dc.relation.ispartofpagefrom315en_US
dc.relation.ispartofpageto326en_US
dc.relation.ispartofissue3en_US
dc.relation.ispartofjournalExpert Opinion on Drug Discoveryen_US
dc.relation.ispartofvolume14en_US
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciencesen_US
dc.subject.fieldofresearchcode1115en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsPharmacology & Pharmacyen_US
dc.subject.keywordsFocal cerebral ischemiaen_US
dc.subject.keywordsmiddle cerebral artery occlusionen_US
dc.titleAnimal models of ischemic stroke and their impact on drug discoveryen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationHermann, DM; Popa-Wagner, A; Kleinschnitz, C; Doeppner, TR, Animal models of ischemic stroke and their impact on drug discovery, Expert Opinion on Drug Discovery, 2019, 14 (3), pp. 315-326en_US
dc.date.updated2019-09-03T00:10:25Z
gro.hasfulltextNo Full Text
gro.griffith.authorPopa-Wagner, Aurel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record